These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 9010698)

  • 1. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Eur J Clin Pharmacol; 1996; 51(3-4):273-6. PubMed ID: 9010698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A; Sundberg S; Ojala-Karlsson P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise.
    Sundberg S; Scheinin M; Illi A; Akkila J; Gordin A; Keränen T
    Br J Clin Pharmacol; 1993 Nov; 36(5):451-6. PubMed ID: 12959293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMT inhibition by high-dose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise.
    Illi A; Sundberg S; Koulu M; Scheinin M; Heinävaara S; Gordin A
    Int J Clin Pharmacol Ther; 1994 Nov; 32(11):582-8. PubMed ID: 7874370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of COMT inhibition with entacapone on cardiorespiratory responses to exercise in patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Gordin A; Kultalahti ER; Teräväinen H; Sovijärvi A
    Parkinsonism Relat Disord; 2002 Jun; 8(5):349-55. PubMed ID: 15177064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of the COMT inhibitor nitecapone for one week on exercise haemodynamics and catecholamine disposition.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Akkila J; Gordin A
    Eur J Clin Pharmacol; 1993; 44(3):287-90. PubMed ID: 8491246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.
    Dingemanse J; Meyerhoff C; Schadrack J
    Br J Clin Pharmacol; 2002 May; 53(5):485-91. PubMed ID: 11994054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine.
    Illi A; Sundberg S; Ojala-Karlsson P; Korhonen P; Scheinin M; Gordin A
    Clin Pharmacol Ther; 1995 Aug; 58(2):221-7. PubMed ID: 7648772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.
    Keränen T; Gordin A; Koulu M; Scheinin M; Antila S; Sundberg S; Wikberg T
    J Neural Transm (Vienna); 1996; 103(6):729-36. PubMed ID: 8836934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exercise hemodynamics and catecholamine metabolism after catechol-O-methyltransferase inhibition with nitecapone.
    Sundberg S; Scheinin M; Ojala-Karlsson P; Kaakkola S; Akkila J; Gordin A
    Clin Pharmacol Ther; 1990 Oct; 48(4):356-64. PubMed ID: 2225697
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
    Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
    Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
    Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
    Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. No change of brain extracellular catecholamine levels after acute catechol-O-methyltransferase inhibition: a microdialysis study in anaesthetized rats.
    Li YH; Wirth T; Huotari M; Laitinen K; MacDonald E; Männistö PT
    Eur J Pharmacol; 1998 Sep; 356(2-3):127-37. PubMed ID: 9774242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
    Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
    J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease.
    Merello M; Lees AJ; Webster R; Bovingdon M; Gordin A
    J Neurol Neurosurg Psychiatry; 1994 Feb; 57(2):186-9. PubMed ID: 8126502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone.
    Keränen T; Gordin A; Karlsson M; Korpela K; Pentikäinen PJ; Rita H; Schultz E; Seppälä L; Wikberg T
    Eur J Clin Pharmacol; 1994; 46(2):151-7. PubMed ID: 8039535
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson's disease.
    Myllylä VV; Sotaniemi KA; Illi A; Suominen K; Keränen T
    Eur J Clin Pharmacol; 1993; 45(5):419-23. PubMed ID: 8112370
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose.
    Heikkinen H; Varhe A; Laine T; Puttonen J; Kela M; Kaakkola S; Reinikainen K
    Br J Clin Pharmacol; 2002 Oct; 54(4):363-71. PubMed ID: 12392583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical advantages of COMT inhibition with entacapone - a review.
    Gordin A; Kaakkola S; Teräväinen H
    J Neural Transm (Vienna); 2004 Oct; 111(10-11):1343-63. PubMed ID: 15340869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.